Astragaloside IV suppresses transforming growth factor-β1-induced epithelial-mesenchymal transition through inhibition of Wnt/β-catenin pathway in glioma U251 cells

• Published in: Bioscience, biotechnology, and biochemistry Vol. 84; no. 7; pp. 1345 - 1352
• Main Authors: Han, Jinming, Shen, Xiaohan, Zhang, Yong, Wang, Suying, Zhou, Leijie
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 02.07.2020; Oxford University Press
• Subjects: Antigens, CD - metabolism; Apoptosis - drug effects; Astragaloside; beta Catenin - antagonists & inhibitors; beta Catenin - metabolism; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Cadherins - metabolism; Cell Line, Tumor; Cell Movement - drug effects; Cell Proliferation - drug effects; central nervous system tumors; epithelial-mesenchymal transition; Epithelial-Mesenchymal Transition - drug effects; Glioma - metabolism; Glioma - pathology; glioma U251 cells; Humans; Saponins - pharmacology; Transforming Growth Factor beta1 - pharmacology; transforming growth factor-β1; Triterpenes - pharmacology; Wnt Signaling Pathway - drug effects; epithelial–mesenchymal transition; transforming growth factor-β1; glioma U251 cells; Astragaloside; central nervous system tumors
• ISSN: 0916-8451; 1347-6947
• DOI: 10.1080/09168451.2020.1737502

Astragaloside IV (AS#IV) has previously demonstrated antitumoractivity. We investigated the effect and mechanisms of AS#IV in relation to epithelial-mesenchymal transition (EMT), viainterference with the Wnt/β-catenin signaling pathway in gliomaU251 cells. Induction of glioma U251 cells by transforming growthfactor (TGF)#β1 activated EMT, including switching E#cadherin toN-cadherin and altering the expression of Wnt/β-catenin signalingpathway components such as vimentin, β-catenin, and cyclin-D1.AS-IV inhibited the viability, invasion, and migration of TGF-β1-induced glioma U251 cells. AS-IV also interfered with the TGF#β1-induced Wnt/β-catenin signaling pathway in glioma U251 cells.These findings indicate that AS#IV prohibits TGF#β1-induced EMTby disrupting the Wnt/β-catenin pathway in glioma U251 cells. AS#IV may thus be a potential candidate agent for treating glioma andother central nervous system tumors. Astragaloside IV interfered with the TGF-β1-induced Wnt/β-catenin signaling pathway in glioma cells.